Stay updated on Anti-PD-1 Antibody With HD IL-2 in Metastatic Melanoma Clinical Trial
Sign up to get notified when there's something new on the Anti-PD-1 Antibody With HD IL-2 in Metastatic Melanoma Clinical Trial page.

Latest updates to the Anti-PD-1 Antibody With HD IL-2 in Metastatic Melanoma Clinical Trial page
- CheckyesterdayChange DetectedMelanoma was removed from the conditions section and MedlinePlus Genetics was removed from related topics.SummaryDifference0.2%

- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check23 days agoChange DetectedRevision notes updated: added Revision v3.5.0 and removed Revision v3.4.3.SummaryDifference0.1%

- Check30 days agoChange DetectedRevision label updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check37 days agoChange DetectedAdded related topics: Melanoma and MedlinePlus Genetics.SummaryDifference0.2%

- Check44 days agoChange DetectedMelanoma and related topics, including MedlinePlus Genetics, were removed.SummaryDifference0.2%

- Check58 days agoChange DetectedSite revision updated to v3.4.2 and the old government funding notices (lapse notice and v3.4.1) have been removed. These are administrative changes and do not affect the study details or core content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

Stay in the know with updates to Anti-PD-1 Antibody With HD IL-2 in Metastatic Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Anti-PD-1 Antibody With HD IL-2 in Metastatic Melanoma Clinical Trial page.